Zologan

Article:

Country of origin: India
Pharm-Group: Spasmoanalgesics

Manufacturers: Pharmaceuticals M.J. (India)
International name: Metamizole + Pitophenone + Fenpiverinium bromide
Synonyms: Baralgetas, Baralgin, Berlon, Bioralgin, Bral, Bralangin, Veralgan, Maksigan, Minalgan, Nebalgan, Revalgin, Renalgan, Spazvin, Spazgan, Spazmalgin, Spazmalgon, Spasmalin, Spasmoanalgan, Spasmogard, Spaznil, Trigan, Trigan-D
Dosage forms: tablets, injection solution
Composition: Active substance: metamizole sodium, pitofenone hydrochloride, fenpiverinium bromide.

Indications for use:

1. pain syndrome due to spasms of smooth muscles of internal organs (including renal colic, hepatic colic, biliary colic, intestinal colic, dysmenorrhea, biliary dyskinesia);
2. for short-term relief of pain due to neuralgia, arthralgia, sciatica;
3. as an auxiliary drug to reduce pain after surgical interventions and diagnostic procedures;
4. for short-term symptomatic treatment of headache, migraine pain, myalgia (for tablets);
5. to reduce elevated body temperature during colds and infectious-inflammatory diseases (for tablets).

Contraindications:

1. severe liver dysfunction;
2. severe renal dysfunction;
3. genetic deficiency of glucose-6-phosphate dehydrogenase;
4. tachyarrhythmia;
5. angle-closure glaucoma;
6. prostatic hyperplasia (with clinical manifestations);
7. inhibition of bone marrow hematopoiesis;
8. intestinal obstruction;
9. megacolon;
10. collapse;
11. acute porphyria;
12. chronic heart failure in the stage of decompensation (for solution for injection);
13. stable and unstable angina (for solution for injection);
14. pregnancy (first trimester and last 6 weeks);
15. lactation period (breastfeeding);
16. hypersensitivity to pyrazolone derivatives and other components of the drug.

Side effect:
Sometimes: allergic reactions (skin rash, itching, very rarely - anaphylactic shock, urticaria), angioedema. In isolated cases: burning sensation in the epigastric region, dry mouth, headache. Possible: dizziness, decreased blood pressure, tachycardia, cyanosis. With long-term use: hematopoietic disorders: thrombocytopenia, leukopenia, agranulocytosis. If you are prone to bronchospasm, it is possible to provoke an attack. In very rare cases: malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome). Rarely (usually with long-term use or when prescribed in high doses): impaired renal function (oliguria, anuria, proteinuria, interstitial nephritis, red urine). Very rare: decreased sweating, accommodation paresis, difficulty urinating. Local reactions: infiltrates at the site of intramuscular injection.

Interaction:
When the drug is used simultaneously with other non-opioid analgesics, a mutual increase in toxic effects is observed. Tricyclic antidepressants, oral contraceptives, allopurinol disrupt the metabolism of metamizole sodium and increase its toxicity. Barbiturates, phenylbutazone and other inducers of microsomal liver enzymes weaken the effect of metamizole sodium. With simultaneous use of the drug with cyclosporine, the level of the latter in the blood decreases. Sedatives and tranquilizers enhance the analgesic effect of metamizole sodium. When prescribing the drug simultaneously with histamine H1 receptor blockers, butyrophenones, phenothiazines, amantadine and quinidine, the m-anticholinergic effect may be enhanced. When used simultaneously with ethanol, a mutual enhancement of effects is observed. When using the drug simultaneously with chlorpromazine or other products